| Position | Action |
|---|---|
| Price reaches $1,200 | Trim one-third of position |
| Price reaches $1,236 | Trim second third of position |
| Price reaches $1,260 | Trim final third of position |
| Pullback to $1,115-$1,130 | Add position sized at 25-50% of aggressive accumulation levels |
| Close below $1,150 on volume | Hard stop triggered; reassess to Underweight |
LLY is a generational compounder at an inflection point, with accelerating revenue growth (+55.5% YoY), expanding competitive moats through $10B capex manufacturing build, and a multi-year GLP-1 demand wave still in early innings.
| Indicator | Value | Signal |
|---|---|---|
| RSI(14) | 51.28 | neutral |
| MACD Line | -0.35 | bearish |
| MACD Signal | +7.74 | — |
| MACD Histogram | -8.09 | bearish |
| 10 EMA | $1,160.94 | bullish |
| 50 SMA | $1,152.95 | bullish |
| 200 SMA | $1,027.51 | bullish |
| Bollinger Upper | $1,229.83 | — |
| Bollinger Middle | $1,172.55 | — |
| Bollinger Lower | $1,115.27 | bullish |
| VWMA(20) | $1,166.67 | neutral |
| ATR(14) | $41.38 | — |
Support: — | Resistance: —
Technical picture is constructive but not yet a confirmed breakout. High-volume reversal off lower Bollinger Band is a strong bullish signal, but stock must clear $1,200 convincingly to neutralize negative MACD histogram and re-engage prior uptrend. Long-term trend remains firmly intact (50 SMA above 200 SMA, price +13.86% above 200 SMA). Current conditions favor HOLD with bullish bias, ready to BUY on confirmed close > $1,200 with volume validation.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Hold at current weight with mechanical trim/add rules; hard stop at $1,150; no hedges; upgrade requires two-of-three technical confirmations.
Hold LLY at current weight with no additions at $1,170. Execute mechanical trim in thirds at $1,200/$1,236/$1,260; add only on pullback to $1,115-$1,130 capped at 25-50% of aggressive sizing. Hard stop at $1,150. No protective puts or collars—2026-08-03 lesson is unambiguous that vol structures destroy alpha on this name. Upgrade to Overweight requires two of three technical confirmations; reassess to Underweight on 50 SMA failure below $1,150 or material competitive/regulatory threat to GLP-1 TAM.
When: Two of three: sustained close above $1,236 on volume >4M, MACD bullish re-cross with histogram turning positive, or volume-validated breakout above prior high
Then: Upgrade to Overweight; consider adding to position
Competitive moat is widening through manufacturing scale, distribution, and pipeline depth
↩ rebuts: “Novo Nordisk competition thesis”
· concedes: Patent cliffs in 2030+ mentioned as long-term risk; Single-product concentration acknowledged (2/3 revenue from GLP-1), though framed as feature not bug; 340B program flagged as 2027 watch item
LLY at $1,170 is priced for perfection with zero margin of safety — the fundamentals are excellent but already fully reflected in a $1T market cap, leaving asymmetric downside risk across technical, fundamental, and competitive dimensions.
· concedes: LLY is a great company with real fundamentals; The GLP-1 franchise is real and the TAM is real; Management is executing on a massive capex build-out; Debt/EBITDA of ~1.0× is manageable in absolute terms; Verzenio, Taltz, and Kisunla are legitimate franchises (though combined they don't offset GLP-1 concentration); Tirzepatide patent protection extends into the late 2030s; The 91% YoY growth is genuinely exceptional
→ vs conservative: Valuation concern over $1T market cap and 41x trailing P/E is 'lazy analysis'—premium valuations follow superior fundamentals; comparable names (Nvidia, Apple, Microsoft) traded at similar premiums during transformative periods
→ vs conservative: Waiting for confirmation above $1,236 means buying 5.7% higher; strong trends require scaling in on pullbacks, not full confirmation
→ vs conservative: Hard stop at $1,150 with trim at $1,200 leaves $30 per share on table treating $1,200 as resistance when it's actually breakout trigger
→ vs conservative: MACD bearish cross from late July is 'ancient history'—momentum indicators lag price action; waiting for MACD confirmation means buying higher
→ vs conservative: Failed $1,229.83 test framed as ceiling is actually constructive—buyers testing within $13 shows demand, not avoidance
→ vs conservative: Intraday distribution candle (5% gap up, $47 selloff) is profit-taking after news-driven pop, not institutional distribution; healthy tape behavior
→ vs conservative: Supply bottleneck narrative is strategic gift—demand pre-existing means zero customer acquisition cost on capex; not a risk but funding for next growth leg
→ vs conservative: Novo Nordisk threat overstated—Lilly's GLP-1 growth widening over Novo, pipeline depth (donanemab, next-gen incretins, oncology) provides multiple shots on goal
→ vs conservative: Fed no-cut scenario (88% probability in 2026) is actually supportive for low-beta quality compounder generating $5B quarterly operating cash flow
→ vs conservative: Sentiment report low confidence due to retail silence is bullish—retail absent at institutional accumulation phase means sustained move higher without blow-off top risk
Market Cap
$1,043.2 B
P/E (TTM)
41.56×
Forward P/E
25.85×
PEG Ratio
1.56
Price/Book
33.5×
EPS (TTM)
$28.15
Forward EPS
$45.25
Dividend Yield
0.62%
Beta
0.506
52-Week High
$1,249.45
52-Week Low
$623.78
50-Day MA
$1,149.37
200-Day MA
$1,026.34
Revenue (Q1 2026)
$19.80 B
Gross Profit (Q1 2026)
$16.22 B
Operating Income (Q1 2026)
$9.78 B
Net Income (Q1 2026)
$7.40 B
Diluted EPS (Q1 2026)
$8.26
EBITDA (Q1 2026)
$10.29 B
Gross Margin
82%
Operating Margin
49.4%
Profit Margin
35.0%
Revenue (TTM)
$72.25 B
Net Income (TTM)
$25.28 B
R&D Spend (Q1 2026)
$3.51 B
SG&A (Q1 2026)
$2.93 B
Special Charges (Q1 2026)
$863 M
Special Charges (Q4 2025)
$627 M
Total Assets (Mar-26)
$116.58 B
Total Liabilities (Mar-26)
$85.38 B
Stockholders' Equity (Mar-26)
$31.20 B
Total Debt (Mar-26)
$43.37 B
Cash & Equivalents (Mar-26)
$5.28 B
Net Debt (Mar-26)
$38.09 B
Net PPE (Mar-26)
$26.54 B
Goodwill & Intangibles (Mar-26)
$13.50 B
Inventory (Mar-26)
$14.53 B
Receivables (Mar-26)
$21.18 B
Current Ratio (Mar-26)
1.50×
Debt/Equity (Mar-26)
1.39×
Operating Cash Flow (Q1 2026)
$5.33 B
Capital Expenditure (Q1 2026)
($2.53) B
Free Cash Flow (Q1 2026)
$2.80 B
Free Cash Flow (TTM)
$9.16 B
Cash Dividends Paid (Q1 2026)
($1.55) B
Share Repurchases (Q1 2026)
($2.36) B
Net Debt Issuance (Q1 2026)
$1.03 B
Business Acquisitions (Q1 2026)
($1.06) B
Ending Cash (Q1 2026)
$5.28 B
Capex Annualized Run-rate
~$10 B
Return on Equity
107.46%
Return on Assets
20.74%
Dividends Paid (TTM)
~$5.5 B
Buybacks (TTM)
~$6.2 B
Net Debt/EBITDA
~1.0×
Strengths
Concerns
Eli Lilly delivered Q1 2026 revenue of $19.80B (+55.5% YoY) and EPS of $8.26 (+170% YoY), driven by tirzepatide's accelerating ramp, with TTM revenue reaching $72.25B and net income of $25.28B; gross margin of 82% and operating margin of 49.4% reflect best-in-class franchise economics. The balance sheet shows stockholders' equity nearly doubling to $31.2B, Debt/Equity improving from 2.44× to 1.39×, and Net Debt/EBITDA at ~1.0×, indicating manageable leverage despite $38.1B net debt. ROE stands at an extraordinary 107.5%, though valuation multiples remain stretched at 41.56× trailing P/E and 33.5× P/B, with key risks centered on GLP-1 competition, patent cliffs, and pricing pressure from IRA/PBM scrutiny.